First-line ICIs in renal cell carcinoma.
Immune checkpoint inhibition
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
10
7
2023
pubmed:
3
7
2023
entrez:
3
7
2023
Statut:
ppublish
Résumé
Treatment of metastatic renal cell carcinoma (mRCC) has radically changed, switching from interferon alfa (IFN-α) and high-dose interleukin-2 (HD IL-2) to new targeted therapies directed against tumoral neoangiogenesis, the mammalian target of the rapamycin (mTOR) pathway and immune checkpoints. Of note, the inhibition of immune checkpoints restores antitumor immune response, therefore promoting immune-mediated elimination of neoplastic cells. The best example of this targeted treatment is represented by PD-1/PD-L1 inhibition that has become the standard of care in mRCC treatment and has improved mRCC patients' prognoses after failure of other targeted therapies. In this manuscript, we review the main therapeutic protocols adopted for mRCC, based on the use of immune checkpoint inhibitors (ICIs) alone or combined with other drugs.
Identifiants
pubmed: 37395601
doi: 10.1080/21645515.2023.2225386
pmc: PMC10332208
doi:
Substances chimiques
Interferon-alpha
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2225386Références
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
Cancer Immunol Immunother. 2008 Aug;57(8):1115-24
pubmed: 18193223
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Eur Urol. 2021 Mar;79(3):339-342
pubmed: 33357997
N Engl J Med. 2021 Aug 19;385(8):683-694
pubmed: 34407342
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Commun. 2016 Aug 30;7:12624
pubmed: 27571927
Lancet Oncol. 2003 Apr;4(4):215-23
pubmed: 12681265
JAMA Netw Open. 2023 May 1;6(5):e2314144
pubmed: 37200035
N Engl J Med. 2015 Nov 5;373(19):1814-23
pubmed: 26406150
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
ESMO Open. 2020 Nov;5(6):e001079
pubmed: 33246931
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
J Immunol. 2008 Jul 1;181(1):346-53
pubmed: 18566400
Ther Adv Urol. 2016 Oct;8(5):319-326
pubmed: 27695530
Eur J Cancer. 2021 Sep;154:120-127
pubmed: 34265504
Ther Adv Urol. 2017 Jun 29;9(8):195-207
pubmed: 29662544
J Clin Oncol. 1995 Mar;13(3):688-96
pubmed: 7884429
Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):77-83
pubmed: 19601920
Lancet Oncol. 2019 Feb;20(2):297-310
pubmed: 30658932
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Nat Med. 2020 Oct;26(10):1519-1530
pubmed: 33020645
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Front Oncol. 2021 Aug 30;11:707214
pubmed: 34527581
Cancer. 2005 Nov 15;104(10):2084-91
pubmed: 16208700
Lancet Oncol. 2022 Feb;23(2):292-303
pubmed: 35032437
Cancer. 2010 Sep 15;116(18):4256-65
pubmed: 20549832
Cancer Immunol Immunother. 2007 Nov;56(11):1743-53
pubmed: 17487490
Lancet Oncol. 2009 Oct;10(10):992-1000
pubmed: 19796751
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Mol Cell Biol. 2005 Nov;25(21):9543-53
pubmed: 16227604
N Engl J Med. 1998 Apr 30;338(18):1272-8
pubmed: 9562581
J Clin Oncol. 2008 Nov 20;26(33):5422-8
pubmed: 18936475
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
N Engl J Med. 2017 Jan 26;376(4):354-366
pubmed: 28121507
Crit Rev Oncol Hematol. 2016 Sep;105:52-64
pubmed: 27372200
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
N Engl J Med. 2007 May 31;356(22):2271-81
pubmed: 17538086
Curr Treat Options Oncol. 2018 Jan 24;19(1):6
pubmed: 29368125
Invest New Drugs. 2012 Oct;30(5):2066-79
pubmed: 22327313
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
J Natl Compr Canc Netw. 2020 Sep;18(9):1160-1170
pubmed: 32886895
Lancet. 2016 Feb 27;387(10021):894-906
pubmed: 26318520
J Clin Oncol. 2009 Jul 10;27(20):3312-8
pubmed: 19451442